EC expanded Merckメs VAXNEUVANCEル indication to include infants, children and adolescents
On Oct. 24, 2022, Merck announced that the European Commission had approved an expanded indication for VAXNEUVANCEル (Pneumococcal 15-valent Conjugate Vaccine) to include active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae (S. pneumoniae) in infants, children and adolescents from 6 weeks to less than 18 years of age.
The approval facilitates availability of VAXNEUVANCE for this population in all 27 European Union (EU) Member States plus Iceland, Norway and Lichtenstein. VAXNEUVANCE is also indicated in the EU for active immunization for the prevention of invasive disease and pneumonia caused by S. pneumoniae in individuals 18 years of age and older.
Tags:
Source: Merck
Credit: